Liquidia (NASDAQ:LQDA) Cut to “Hold” at Lifesci Capital

Lifesci Capital lowered shares of Liquidia (NASDAQ:LQDA) from an outperform rating to a hold rating in a report published on Wednesday morning, Marketbeat Ratings reports. They currently have $90.00 target price on the stock.

Several other equities analysts have also recently weighed in on the company. Jefferies Financial Group restated a “buy” rating and issued a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Liquidia in a research report on Friday, July 17th. BTIG Research raised their price target on Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research report on Monday, June 22nd. Oppenheimer set a $75.00 price target on Liquidia in a research note on Friday, June 5th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $68.00 price objective on shares of Liquidia in a research report on Thursday, June 4th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $98.08.

Liquidia Stock Performance

LQDA stock opened at $74.44 on Wednesday. The company has a quick ratio of 2.03, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. Liquidia has a twelve month low of $21.15 and a twelve month high of $93.61. The business’s fifty day moving average is $78.67 and its 200-day moving average is $55.13. The company has a market cap of $6.62 billion, a P/E ratio of 54.34 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to analyst estimates of $168.48 million. Liquidia had a return on equity of 149.65% and a net margin of 30.74%.The company’s revenue for the quarter was up 1842.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.49) earnings per share. Equities research analysts forecast that Liquidia will post 2.74 EPS for the current year.

Insider Buying and Selling at Liquidia

In other news, Director Paul B. Manning sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $63.91, for a total value of $12,782,000.00. Following the transaction, the director owned 716,311 shares in the company, valued at approximately $45,779,436.01. The trade was a 21.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Stephen M. Bloch sold 242,269 shares of Liquidia stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares of the company’s stock, valued at approximately $82,838,639.12. This trade represents a 17.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 1,756,861 shares of company stock valued at $122,981,112. 25.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Northwestern Mutual Wealth Management Co. purchased a new position in Liquidia during the 4th quarter valued at about $25,000. Covestor Ltd grew its stake in Liquidia by 41.9% in the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Liquidia in the 2nd quarter worth approximately $25,000. Globeflex Capital L P bought a new position in shares of Liquidia in the 2nd quarter worth $175,000. Finally, Fluent Financial LLC purchased a new stake in shares of Liquidia during the 2nd quarter valued at $287,000. Institutional investors own 64.54% of the company’s stock.

More Liquidia News

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: YUTREPIA sales drove second-quarter revenue to $171.68 million, exceeding the $168.48 million consensus estimate, while revenue increased more than 1,800% year over year. Management also highlighted rising demand for the inhaled lung-disease treatment. LQDA Q2 Earnings Top
• Positive Sentiment: Liquidia is targeting more than $1 billion in 2027 net revenue as YUTREPIA gains market share and helps fund a broader inhaled-treprostinil pipeline, providing investors with a significant long-term growth narrative. LQDA Earnings Call Highlights
• Positive Sentiment: Bank of America raised its price target from $79 to $92, while BTIG Research and Needham indicated further appreciation potential. These targets support the bullish case, although Bank of America retained a neutral rating. Bank of America Price Target
• Neutral Sentiment: Lifesci Capital initiated or maintained a Market Perform view, reflecting more balanced expectations despite the company’s strong commercial momentum. Lifesci Capital Rating
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share narrowly missed the $0.76 consensus estimate. The results triggered a negative reaction despite the revenue beat, particularly after LQDA had already risen sharply this year. Liquidia Shares Gap Down
• Negative Sentiment: HC Wainwright lowered its third-quarter 2026 EPS forecast to $1.01 from $1.15, adding pressure to near-term expectations. With a reported price-to-earnings ratio above 54, investors may be particularly sensitive to estimate reductions. HC Wainwright Estimate Revision

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).